Pravastatin sodium

• CAT Number: A000953
• CAS Number: 81131-70-6
• Molecular Formula: C23H35O7 • Na
• Molecular Weight: 446.50
• Purity: ≥95%
• Synonyms: CS-514 Sodium
• Target: HMG-CoA Reductase
• Solubility: >13.2mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: sodium;(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate
• InChI: InChI=1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1
• InChIKey: VWBQYTRBTXKKOG-IYNICTALSA-M
• SMILES: CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)[O-])O)O)O.[Na+]

Pravastatin sodium（Cat No.:A000953）is a potent HMG-CoA reductase inhibitor widely used to lower cholesterol and prevent cardiovascular diseases. By inhibiting cholesterol synthesis in the liver, it effectively reduces low-density lipoprotein (LDL) cholesterol levels while increasing high-density lipoprotein (HDL) cholesterol. This makes pravastatin sodium an essential medication for managing hypercholesterolemia and reducing the risk of heart attacks and strokes. Its favorable pharmacokinetic profile, including minimal interaction with the cytochrome P450 system, reduces the likelihood of drug interactions, making it suitable for patients with complex medication regimens.

Reference

Terahara A. US Patent 4,346,227 (1982).

Terahara A. US Patent 4,537,859 (1985).

Effect of CS-514, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on lipoprotein and apolipoprotein in plasma of hypercholesterolemic diabetics. Yoshino G. et al. Diabetes Res. Clin. Pract. 1986, 2, 179.

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Tsujita Y. et al. Biochim Biophys Acta 1986, 877, 50.